Business
Pharvaris Outlines 2026 Strategic Priorities
Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksEstimated cash runway into 1H2027 ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: P
About this update from Pharvaris N.v.
[{"type":"image","alt":"Pharvaris N.V.","displaySize":"","headline":null,"caption":"Pharvaris N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/0efc0ce5210d066470f326abda980f7b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JdraIoW6kPmv1O4DeeShmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0efc0ce5210d066470f326abda980f7b","width":300,"height":44}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Estimated cash runway into 1H2027","length":33,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":427,"olType":false},{"type":"text","content":"ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today outlined its strategic priorities for 2026.","length":406,"tagName":"p"},{"type":"text","content":"“The readout of Pharvaris’ first pivotal Phase 3 study, RAPIDe-3, in December was the culmination of a decade of scientific rigor, operational and financial diligence, executional excellence, and, most importantly, community engagement and commitment,” said Berndt Modig, Chief Executive Officer of Pharvaris. “The data reported in December build upon Pharvaris’ legacy in HAE drug development, and we believe demonstrate deucrictibant’s potentially differentiated profile and potential to become a new standard of care for on-demand HAE treatment of attacks. Our team’s ability to conduct the most diverse Phas...